BrickBio

Executive Summary

BrickBio is a private biotechnology company based in Cambridge, MA, founded in 2019, that has developed a proprietary bioconjugation platform for the site-specific and site-selective modification of antibodies and other proteins. The technology enables precise incorporation of synthetic amino acids to create homogeneous, optimized biologics, with a primary focus on improving antibody-drug conjugates (ADCs) and protein therapeutics. By enhancing therapeutic windows and patient outcomes, BrickBio's approach addresses key limitations of conventional conjugation methods, such as heterogeneity and suboptimal efficacy. Despite being in early stages with no disclosed funding or pipeline products, the platform holds potential for partnerships with larger biopharma companies seeking next-generation ADC technologies.

Upcoming Catalysts (preview)

• Q4 2026Announcement of Series A Funding Round70% success
• Q2 2027Presentation of Preclinical Data for Lead ADC Program50% success
• Q1 2027Establishment of a Major Pharmaceutical Partnership40% success